Citations

Clear

65 citation(s) found for "Pollack, P".

Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
Sandborn, William J. , Rutgeerts, Paul, Enns, Robert, D’Haens, Geert , Rosenfeld, Marie R., Kent, Jeffrey D., Pollack, Paul F., Hanauer, Stephen B. , Colombel, Jean‐Frédéric , Panaccione, Remo , Li, Ju

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 146 | Issue: 12 | Pages: 829-838

10.7326/0003-4819-146-12-200706190-00159 | PMID 17470824 Get It

Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association
Garber, Jeffrey R., Cobin, Rhoda H., Gharib, Hossein, Hennessey, James V. , Klein, Irwin, Mechanick, Jeffrey I. , Singer, Peter, Pessah‐Pollack, Rachel

Mayo Clinic

Thyroid | September 6, 2012 | Volume: 22 | Issue: 12 | Pages: 1200-1235

10.1089/thy.2012.0205 | PMID 22954017 Get It

Spontaneous Rupture of a Peripheral Artery: Report of Case
Pollack, Albert A., Hines, Edgar A., Janes, Joseph M.

Mayo Clinic

Circulation | June 11, 2012 | Volume: 1 | Issue: 4 | Pages: 613-614

10.1161/01.cir.1.4.613 Get It

The case history of a patient with apparent spontaneous rupture of the posterior tibial artery is presented, with a brief review of the previously reported cases.
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson, Andrew J. , Scardino, Peter T. , Kattan, Michael W. , Pisansky, Thomas M. , Slawin, Kevin M., Klein, Eric A. , Anscher, Mitchell S. , Michalski, Jeff M. , Lin, Daniel W. , Forman, Jeffrey D., Zeléfsky, Michael J. , Kestin, Larry L. , Roehrborn, Claus G. , Catton, Charles , DeWeese, Theodore L. , Liauw, Stanley L. , Valicenti, Richard K., Kuban, Deborah A., Pollack, Alan , Sandler, Howard M. , Klein, Eric A , Liauw, Stanley L , Kattan, Michael W

Mayo Clinic

Journal of Clinical Oncology | May 19, 2007 | Volume: 25 | Issue: 15 | Pages: 2035-2041

10.1200/jco.2006.08.9607 | PMID 17513807 Get It

Purpose An increasing serum prostate-specific antigen (PSA) level is the initial sign of recurrent prostate cancer among patients treated with radical prostatectomy. Salvage radiation therapy (SRT) may eradicate locally recurrent cancer, but studies to distinguish local from systemic recurrence lack adequate sensitivity and specificity. We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence. Patients and Methods Using multivariable Cox regression analysis, we constructed a model to predict the probability of disease progression after SRT in a multi-institutional cohort of 1,540 patients. Results The 6-year progression-free probability was 32% (95% CI, 28% to 35%) overall. Forty-eight percent (95% CI, 40% to 56%) of patients treated with SRT alone at PSA levels of 0.50 ng/mL or lower were disease free at 6 years, including 41% (95% CI, 31% to 51%) who also had a PSA doubling time of 10 months or less or poorly differentiated (Gleason grade 8 to 10) cancer. Significant variables in the model were PSA level before SRT (P < .001), prostatectomy Gleason grade (P < .001), PSA doubling time (P < .001), surgical margins (P < .001), androgen-deprivation therapy before or during SRT (P < .001), and lymph node metastasis (P = .019). The resultant nomogram was internally validated and had a concordance index of 0.69. Conclusion Nearly half of patients with recurrent prostate cancer after radical prostatectomy have a long-term PSA response to SRT when treatment is administered at the earliest sign of recurrence. The nomogram we developed predicts the outcome of SRT and should prove valuable for medical decision making for patients with a rising PSA level.
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
Hidalgo, Manuel , Buckner, Jan C. , Erlichman, Charles , Pollack, Marilyn S., Boni, Joseph , Dukart, Gary, Marshall, Bonnie, Speicher, Lisa A., Rowinsky, Eric K. , Moore, Laurence

Mayo Clinic

Clinical Cancer Research | October 4, 2006 | Volume: 12 | Issue: 19 | Pages: 5755-5763

10.1158/1078-0432.ccr-06-0118 | PMID 17020981 Get It

Abstract Purpose: Patients with advanced cancer received temsirolimus (Torisel, CCI-779), a novel inhibitor of mammalian target of rapamycin, i.v. once daily for 5 days every 2 weeks to determine the maximum tolerated dose, toxicity profile, pharmacokinetics, and preliminary antitumor efficacy. Experimental Design: Doses were escalated in successive cohorts of patients using a conventional phase I clinical trial design. Samples of whole blood and plasma were collected to determine the pharmacokinetics of temsirolimus and sirolimus, its principal metabolite. Results: Sixty-three patients were treated with temsirolimus (0.75-24 mg/m2/d). The most common drug-related toxicities were asthenia, mucositis, nausea, and cutaneous toxicity. The maximum tolerated dose was 15 mg/m2/d for patients with extensive prior treatment because, in the 19 mg/m2/d cohort, two patients had dose-limiting toxicities (one with grade 3 vomiting, diarrhea, and asthenia and one with elevated transaminases) and three patients required dose reductions. For minimally pretreated patients, in the 24 mg/m2/d cohort, one patient developed a dose-limiting toxicity of grade 3 stomatitis and two patients required dose reductions, establishing 19 mg/m2/d as the maximum acceptable dose. Immunologic studies did not show any consistent trend toward immunosuppression. Temsirolimus exposure increased with dose in a less than proportional manner. Terminal half-life was 13 to 25 hours. Sirolimus-to-temsirolimus exposure ratios were 0.6 to 1.8. A patient with non–small cell lung cancer achieved a confirmed partial response, which lasted for 12.7 months. Three patients had unconfirmed partial responses; two patients had stable disease for ≥24 weeks. Conclusion: Temsirolimus was generally well tolerated on this intermittent schedule. Encouraging preliminary antitumor activity was observed.